Leading Companies
35 of 35
Searching for:
Id |
Company |
Platforms |
Focus |
TrialStage |
Key Products |
Partners |
Approvals |
Website |
|---|---|---|---|---|---|---|---|---|
| 12 | Daiichi Sankyo Japan | mRNA (LNP) | COVID-19 | Approved booster vaccine in Japan | Daichirona (DS-5670) | Government of Japan | Japanese Ministry of Health approval | https://www.daiichisankyo.com |
| 34 | Walvax Biotechnology China | mRNA (LNP) | COVID-19 | Approved in China | AWcorna (with Abogen) | Abogen Biosciences | Conditional approval in China; EUA in Indonesia | https://www.walvax.com |
| 8 | BioNTech SE Germany | mRNA (nucleoside-modified), LNP | COVID-19, malaria, TB, shingles, personalized cancer vaccines | COVID-19 approved; multiple infectious disease & oncology trials ongoing | Comirnaty (with Pfizer), iNeST personalized cancer vaccines | Pfizer, Roche/Genentech | Global approval for COVID-19 | https://www.biontech.com/ |
| 3 | Arcturus Therapeutics United States | saRNA (self-amplifying mRNA) + LNP | COVID-19, influenza, rare diseases | COVID-19 vaccine approved (KOSTAIV®); influenza candidates in trials | ARCT-154 (KOSTAIV), saRNA influenza vaccines | CSL Seqirus, Meiji Seika | EMA + European Commission approval for COVID-19 vaccine | https://arcturusrx.com/ |
| 25 | Pfizer (via BioNTech) United States | mRNA (via BioNTech) | COVID-19 vaccine, influenza, personalized cancer vaccines | COVID-19 vaccine approved; flu mRNA in Phase 3; cancer vaccines in trials | Comirnaty (with with BioNTech, COVID-19 mRNA vaccine) | BioNTech; Acuitas | Approved in global markets for COVID-19 | https://pfizer.com/ |
| 1 | Abogen Biosciences China | mRNA delivered via LNP | COVID-19 vaccines; oncology (IL-12 mRNA for solid tumors) | COVID-19 vaccine in Phase 3; cancer IL-12 program in Phase 2 | AWcorna (COVID-19 mRNA vaccine), ABO2011 (oncology) | Collaboration with local biotech & research institutes (Asia-focused)/ Walvax Biotechnology | Not yet approved vaccine products (preclinical phase) | https://www.abogenbio.com/ |
| 22 | MalarVx, Inc United States | repRNA (self-amplifying RNA), LIONTM delivery system (via HDT Bio collaboration) | Development of next-generation RNA vaccines targeting Plasmodium species (malaria) | Early clinical-stage (Phase 1/IND-enabling programs for malaria vaccine candidates) | repRNA malaria vaccine candidates (preclinical-early clinical)/ Vaccine constructs aimed at multi-stage malaria antigens | HDT Bio Corp. (repRNA + LIONTM delivery technology)/ Global malaria research collaborators & academic institutes | Not yet | https://malarvx.com |
| 33 | Vaxess Technologies United States | mRNA + thermostable delivery systems (MIMIXTM microneedle patches) | Heat-stable mRNA vaccines; next-generation delivery technologies | Early development (preclinical/Phase 1 preparation) | MIMIXTM patch-based RNA vaccine delivery system | DARPA; academic institutions in the U.S | None | https://www.vaxess.com |
| 30 | Shenzhen Kangtai Biological Products (BioKangtai) China | Multiple vaccine platforms; building mRNA R&D capacity | COVID-19 and additional infectious-disease pipeline | Early R&D | mRNA COVID-19 candidate | Chinese vaccine research institutes | None for mRNA yet | https://www.kangtai.com.cn |
| 24 | NanoRibo (Shanghai Biotechnology Co., Ltd.) China | mRNA + RNA drug technologies | mRNA vaccines and RNA-based therapeutics for infectious diseases | Early-stage R&D (preclinical) | mRNA vaccine candidates under internal development | Chinese academic institutions | None | http://www.nanoribo.com/ |
| 16 | Gennova Biopharmaceuticals India | saRNA + nano-emulsion delivery | COVID-19 and Omicron boosters | Emergency Use Authorization for two vaccines in India | GEMCOVAC-19; GEMCOVAC-OM | HDT Bio; DBT India; CEPI | EUA (India) | https://gennova.bio/ |
| 32 | Strand Therapeutics Unites States | programmable saRNA | IL-12 cancer immunotherapy | IND-active; early clinical development | STX-001 | - | None | https://strandtx.com |
| 23 | Moderna United States | mRNA with lipid nanoparticle (LNP) systems | COVID-19, influenza, RSV, CMV, HIV; cancer vaccines | Multiple approved; several in Phase 3 | Spikevax (COVID-19 mRNA vaccine); mRNA-1010 (flu); V940 (cancer) | Collaboration with NIH, Merck, BARDA, CEPI | FDA, EMA approval for COVID-19 vaccines | https://modernatx.com |
| 28 | RNAimmune, Inc. United States | mRNA (LNP) | COVID-19 booster; RSV; KRAS cancer vaccines | Phase 1 | RV-1730 (COVID booster), RV-1770 (RSV) | Sirnaomics | None | https://rnaimmune.com |
| 15 | eTheRNA Immunotherapies Belgium | mRNA (TriMix platform) | Melanoma and HPV-associated cancers | Phase 1/2 | TriMix-based melanoma vaccine | ConserV Bioscience; Grand Pharma | None | https://www.etherna.be |
| 29 | Sanofi (mRNA Center of Excellence) France | mRNA (various formats) | Influenza; COVID-19 (discontinued) | Phase 1/2 (flu) | MRT5400/5401 (flu) | Translate Bio (acquired) | None | https://sanofi.com |
| 27 | RNAimmune, Inc United States (Maryland)/ R&D presence in China | mRNA vaccine platform/ mRNA therapeutics platform/ Lipid nanoparticle (LNP) delivery (via Sirnaomics collaboration | Infectious-disease vaccines (RSV, COVID-19 variants, influenza)/ Cancer vaccines (e.g., KRAS-targeting) | Phase 1: RV-1770 (mRNA vaccine for RSV; FDA IND cleared)/ Preclinical programs for COVID-19, influenza, and oncology | RV-1770 – mRNA vaccine candidate for RSV (IND cleared by U.S. FDA)/ mRNA COVID-19 next-gen booster (preclinical)/ KRAS-targeting cancer mRNA programs | Sirnaomics (parent company; technology provider)/ International collaborations in infectious disease & oncology | FDA IND clearance for RV-1770 (RSV mRNA vaccine candidate) | https://www.rnaimmune.com |
| 17 | Gritstone Bio United States | samRNA + viral vector boosts | Personalized cancer vaccines; next-gen COVID vaccine | Phase 2 | GRANITE (cancer vaccine) | NIAID/NIH | None | https://gritstonebio.com/ |
| 26 | Providence Therapeutics Canada | mRNA (LNP) | COVID-19; rabies; shingles | Phase 2 (COVID) | PTX-COVID19-B; PTX-COVID19-M1 | Everest Medicines (former) | None | https://providencetherapeutics.com |
| 18 | HDT Bio Corp. United States | saRNA (repRNA) + LION delivery | COVID-19; malaria; cancer | Phase 2 (COVID-19) | HDT-301 (saRNA COVID-19 vaccine) | Gennova; NCI; Brazilian institutes | Technology used in Indian EUA vaccines | https://hdt.bio/ |
| 11 | CureVac Germany | mRNA, next-gen mRNA therapies/ LNP | Next-generation COVID-19 vaccines; influenza; cancer (now part of BioNTech) | Phase 2/3 (COVID and flu with GSK), now advancing cancer mRNA projects | CV2CoV, mRNA flu vaccines | Previously partnered with GSK, now acquired by BioNTech | Some derivatives in Phase trials, no major COVID-19 approval like Moderna/Pfizer | https://www.curevac.com/ |
| 2 | Afrigen Biologics (with Biovac) South Africa | mRNA (WHO tech transfer) | COVID-19; Rift Valley fever (planned) | Preclinical | First African-developed mRNA COVID-19 lab vaccine | WHO mRNA Technology Transfer Hub; Biovac (Core hub for WHO mRNA technology transfer in Africa) | None yet | https://afrigen.co.za |
| 6 | BioGeneric Pharma Eygpt | mRNA (WHO tech transfer) | COVID-19 | Preclinical | mRNA COVID-19 candidate | WHO; Afrigen | None | https://biogenericpharma.com |
| 7 | Biological E Ltd. India | mRNA (WHO tech transfer) | COVID-19 | Preclinical | mRNA COVID-19 candidate | WHO Tech Transfer Hub | None | https://biologicale.com |
| 10 | Chimeron Bio United States | RNA therapeutics (including mRNA vaccines), self-assembling delivery vectors | Cancer immunotherapy; infectious-disease vaccines | Preclinical | Platform for tumor-targeted RNA vaccines | U.S. research institutes; biotech accelerators | None | https://www.chimeron.com |
| 19 | Hilleman Laboratories Singapore | mRNA (exploratory), viral vector, protein-based vaccine platforms | Early-stage vaccine discovery and global-health vaccine delivery technologies (hand, foot, and mouth disease (HFMD); dengue; human papillomavirus; and malaria | Preclinical | R&D programs for mRNA vaccine innovation | MSD (Merck); Wellcome Trust; global academic centers | None | https://hilleman-labs.org/ |
| 20 | Incepta Vaccine Ltd. Bangladesh | mRNA (WHO tech transfer) | COVID-19 | Preclinical | COVID mRNA candidate | WHO | None | https://inceptavaccine.com |
| 21 | Institut Pasteur de Dakar Senegal | mRNA (WHO tech transfer) | COVID-19 | Preclinical | COVID mRNA candidate | WHO; Africa CDC | None | https://pasteur.sn |
| 31 | Strand Therapeutics United States | mRNA engineering (target proteins, LNP) | mRNA programs targeting protein complexes for therapeutics & vaccines | Preclinical & early development (focus on protein modulation) | Multiple pipeline candidates under research | Partners with MIT & Biotech networks | No major regulatory approvals yet (R&D stage) | https://www.strandtx.com/ |
| 4 | Bio-Manguinhos / Fiocruz Brazil | mRNA (WHO tech transfer) | COVID-19 and regional diseases | Preclinical (building internal platform) | mRNA COVID-19 candidate | WHO/PAHO; CEPI | None | https://www.fiocruz.br |
| 5 | Biofarma Indonesia | mRNA (via WHO mRNA Technology Transfer Programme) | COVID-19; future expansion into regional infectious diseases | Preclinical (developing local mRNA production capability) | mRNA COVID-19 prototype (under development) | WHO mRNA Technology Transfer Hub; Indonesian government | None | https://www.biofarma.co.id |
| 13 | Dei BioPharma Ltd Uganda | Exploring mRNA-based vaccine and therapeutic development | Capacity-building for infectious-disease vaccines (e.g., malaria) and future mRNA therapeutics | Preclinical (infrastructure development stage) | mRNA vaccine R&D program (early-stage) | African biotech networks; Ugandan Ministry of Health | None | https://deibiopharma.com |
| 37 | RiboPro Netherland | RNA technologies (custom RNA synthesis, modification; not vaccine-focused platform) | Research-grade RNA tools, therapeutic RNA development support | Preclinical / research-stage (no known clinical vaccine programs) | Custom mRNA, miRNA, siRNA synthesis services | Academic institutions and biotech collaborations/ R&D | No approved vaccine or therapeutic products | https://www.ribopro.com/ |
| 14 | Entos Pharmaceuticals, Inc Canada | mRNA; DNA plasmid; Fusogenix™ lipid nanoparticle delivery | Infectious-disease mRNA vaccines and gene-delivery applications | Preclinical to early-clinical programs | FusogenixTM platform for mRNA vaccination and gene therapy | University of Alberta; Canadian government innovation programs | Not yet | https://entospharma.com/ Known for a next-generation LNP system enabling efficient intracellular delivery of mRNA for vaccines |
| 9 | Capstan Therapeutics Unites States | mRNA-enabled cell therapy; in-vivo mRNA reprogramming technology | Immunotherapy, regenerative medicine, potential vaccine applications | Preclinical/IND-enabling | In-vivo mRNA delivery platform for reprogramming immune cells | University of Pennsylvania; major U.S. biotech VC groups | None | https://www.capstantx.com |